Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), is associated with statistically fewer heart attacks than Boston Scientific's Taxus® DES. Dr. Martin B. More at...
The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy -- heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding. More at...
Most elective angioplasties are performed without first conducting a noninvasive stress test to determine whether the procedure is necessary, according to a study published Wednesday in the Journal of the American Medical Association, the Milwaukee Journal Sentinel reports. For the study, researchers analyzed 23,887 Medicare claims and 1,630 private insurance claims. More at...
During heart failure the body reacts to the production of the hormone aldosterone. Too much aldosterone can stiffen and damage the muscles of the heart. Dutch researcher Luc Roumen has optimised compounds that inhibit the production of this hormone and looked at their optimum dosage. The compounds were manufactured by the companies Schering-Plough and SyMO-Chem BV and a drug patent has been applied for. Luc Roumen has developed a new therapy for the prevention of heart failure. More at...
Boston Scientific Corporation (NYSE: BSX) announced positive one-year results from the Intercontinental and European launch phases of its global TAXUS OLYMPIA registry, the world's largest prospective, post-approval registry for a single drug-eluting stent (DES). More at...
Boston Scientific Corporation (NYSE: BSX) announced results from an analysis of the HORIZONS AMI trial. More at...
A blunt traumatic injury to the aorta, the body's main artery, is one of the leading causes of death following a vehicle crash. If it is not treated rapidly, the patient is at serious risk for artery rupture, which is nearly always fatal. Surgeons from the University of Maryland Medical Center have evaluated various treatments for this type of traumatic aortic injury, including a newer, less invasive procedure that enables them to fix the artery without making an incision. More at...
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) and European CE Mark approval of the Angio-Seal™ Evolution™ Vascular Closure Device. The approval and global launch was announced at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. More at...
Thursday, October 16, 2008
What Can You Do to Fight a Systemic Yeast Infection?
Everyone has yeast called Candida albicans in their intestinal tracts. If we have a healthy immune system and plenty of good bacteria present, they will keep this fungus under control. If, for some reason, the balance of good bacteria gets out of whack, the Candida albicans can invade the entire body. When it does, you may see symptoms such as a vaginal yeast infection or thrush. If the case becomes severe, it can even spread to the whole body as a systemic yeast infection.
Cancer Screenings Are Available For Many, But Not Used
Cancer Screenings Are Available For Many, But Not Used
Medicaid recipients age 50 and older are falling short of national cancer screening objectives. According to a report published in the October 13 issue of Archives of Internal Medicine, only about half receive colorectal, breast, and cervical cancer screening tests that the government recommends. Cancers of the colon, breast, and cervix can be detected early and have the potential to be cured.
November Is National Alzheimer's Disease Awareness Month
Twenty five years ago, November was designated as National Alzheimer's Disease Awareness Month. At the time, fewer than 2 million Americans had Alzheimer's. Today, as many as 5.2 million Americans are living with Alzheimer's disease - 120,000 of them in Massachusetts. Alzheimer's can occur as young as age 35, and is currently the sixth leading cause of death in the country. By 2050, 11 to 16 million people will likely have Alzheimer's.
Provectus Announces First Peer-Reviewed Publication On PV-10 In "Melanoma Research"
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that "Melanoma Research" has published a paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D.
Women Needed For Breast Cancer Prevention Trial, Manchester, England
Manchester women at high risk of developing breast cancer are being urged to take part in a pioneering research programme into the prevention of the disease. The Genesis Appeal, the UK's only charity dedicated entirely to the prevention of breast cancer, is recruiting women to take part in the International Breast Cancer Intervention Study (IBIS II).
New issue of Diabetic Hypoglycaemia discusses mortality differences in ACCORD and ADVANCE studies
Diabetic Hypoglycaemia, the influential online diabetes journal published by ESP Bioscience, leads its new issue with a topical editorial, authored by Professor Simon Heller, one of the ADVANCE investigators, and Dr Rory McCrimmon.
AACR And Pancreatic Cancer Action Network Provide Over $1.2 Million In Funds For Pancreatic Cancer Research
The American Association for Cancer Research is accepting applications for grants supporting pancreatic cancer research. The deadline for applications is November 10, 2008. The grant terms will begin on July 1, 2009. Pancreatic cancer is the fourth leading cause of cancer death in the United States.
Breakthrough Cancer Pain - Archimedes Pharma Announces First Positive Phase III Clinical Trial Results For NasalFent
Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces positive headline Phase III results for NasalFent®, the Company's innovative fentanyl citrate nasal spray, developed to provide fast, effective and convenient treatment for breakthrough cancer pain.
Medicaid recipients age 50 and older are falling short of national cancer screening objectives. According to a report published in the October 13 issue of Archives of Internal Medicine, only about half receive colorectal, breast, and cervical cancer screening tests that the government recommends. Cancers of the colon, breast, and cervix can be detected early and have the potential to be cured.
November Is National Alzheimer's Disease Awareness Month
Twenty five years ago, November was designated as National Alzheimer's Disease Awareness Month. At the time, fewer than 2 million Americans had Alzheimer's. Today, as many as 5.2 million Americans are living with Alzheimer's disease - 120,000 of them in Massachusetts. Alzheimer's can occur as young as age 35, and is currently the sixth leading cause of death in the country. By 2050, 11 to 16 million people will likely have Alzheimer's.
Provectus Announces First Peer-Reviewed Publication On PV-10 In "Melanoma Research"
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that "Melanoma Research" has published a paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D.
Women Needed For Breast Cancer Prevention Trial, Manchester, England
Manchester women at high risk of developing breast cancer are being urged to take part in a pioneering research programme into the prevention of the disease. The Genesis Appeal, the UK's only charity dedicated entirely to the prevention of breast cancer, is recruiting women to take part in the International Breast Cancer Intervention Study (IBIS II).
New issue of Diabetic Hypoglycaemia discusses mortality differences in ACCORD and ADVANCE studies
Diabetic Hypoglycaemia, the influential online diabetes journal published by ESP Bioscience, leads its new issue with a topical editorial, authored by Professor Simon Heller, one of the ADVANCE investigators, and Dr Rory McCrimmon.
AACR And Pancreatic Cancer Action Network Provide Over $1.2 Million In Funds For Pancreatic Cancer Research
The American Association for Cancer Research is accepting applications for grants supporting pancreatic cancer research. The deadline for applications is November 10, 2008. The grant terms will begin on July 1, 2009. Pancreatic cancer is the fourth leading cause of cancer death in the United States.
Breakthrough Cancer Pain - Archimedes Pharma Announces First Positive Phase III Clinical Trial Results For NasalFent
Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces positive headline Phase III results for NasalFent®, the Company's innovative fentanyl citrate nasal spray, developed to provide fast, effective and convenient treatment for breakthrough cancer pain.
The Problem of Kidney Neoplasm You Should Know
Another regularly employed word about neoplasm is "kidney masses. Literally translated, the word neoplasm is a new growth. Neoplasms are divided into malignant growths (also identified as cancer), which possess the capability to develop and extend surrounding the body. Non-malignant or benign neoplasms are tissue masses that develop but are not able of extending around the body. It is essential to notice that a benign neoplasm of the kidney could develop and lead to troubles like bleeding although it does not extend by metastasis.
Subscribe to:
Posts (Atom)
